Free Trial

Phreesia, Inc. (NYSE:PHR) Insider Yvonne Hui Sells 388 Shares

Phreesia logo with Medical background

Phreesia, Inc. (NYSE:PHR - Get Free Report) insider Yvonne Hui sold 388 shares of the stock in a transaction on Friday, January 10th. The stock was sold at an average price of $27.85, for a total transaction of $10,805.80. Following the completion of the sale, the insider now owns 26,517 shares in the company, valued at $738,498.45. The trade was a 1.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Yvonne Hui also recently made the following trade(s):

  • On Tuesday, October 15th, Yvonne Hui sold 2,791 shares of Phreesia stock. The shares were sold at an average price of $20.92, for a total value of $58,387.72.

Phreesia Stock Down 0.3 %

NYSE PHR traded down $0.07 on Monday, reaching $26.61. The company had a trading volume of 434,990 shares, compared to its average volume of 444,855. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.77. Phreesia, Inc. has a 1 year low of $17.07 and a 1 year high of $29.16. The firm has a 50-day moving average of $22.87 and a 200-day moving average of $22.63. The firm has a market capitalization of $1.55 billion, a PE ratio of -18.10 and a beta of 0.94.

Phreesia (NYSE:PHR - Get Free Report) last posted its quarterly earnings data on Monday, December 9th. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.04. The firm had revenue of $106.80 million for the quarter, compared to the consensus estimate of $106.33 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The firm's revenue was up 16.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.58) EPS. On average, equities research analysts anticipate that Phreesia, Inc. will post -1.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Phreesia

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Versor Investments LP bought a new position in Phreesia in the 3rd quarter valued at about $694,000. Zacks Investment Management bought a new stake in shares of Phreesia in the 3rd quarter worth $631,000. Sei Investments Co. lifted its holdings in shares of Phreesia by 135.3% in the second quarter. Sei Investments Co. now owns 165,327 shares of the company's stock valued at $3,505,000 after buying an additional 95,058 shares during the period. State Street Corp boosted its stake in Phreesia by 7.1% during the third quarter. State Street Corp now owns 1,327,586 shares of the company's stock valued at $30,256,000 after buying an additional 88,517 shares in the last quarter. Finally, Barclays PLC grew its holdings in Phreesia by 83.6% during the third quarter. Barclays PLC now owns 94,929 shares of the company's stock worth $2,163,000 after acquiring an additional 43,225 shares during the period. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on PHR shares. JMP Securities restated a "market outperform" rating and issued a $30.00 target price on shares of Phreesia in a research report on Tuesday, December 10th. KeyCorp increased their target price on shares of Phreesia from $28.00 to $30.00 and gave the company an "overweight" rating in a research report on Wednesday, January 8th. Citigroup increased their price objective on shares of Phreesia from $31.00 to $35.00 and gave the company a "buy" rating in a report on Friday. Needham & Company LLC restated a "buy" rating and issued a $29.00 price target on shares of Phreesia in a research report on Friday. Finally, Truist Financial boosted their price target on shares of Phreesia from $31.00 to $34.00 and gave the company a "buy" rating in a research report on Wednesday, December 11th. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $31.00.

Check Out Our Latest Report on Phreesia

About Phreesia

(Get Free Report)

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

See Also

Insider Buying and Selling by Quarter for Phreesia (NYSE:PHR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Phreesia Right Now?

Before you consider Phreesia, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phreesia wasn't on the list.

While Phreesia currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

7 Large-Cap Stocks Headed for Strong, Steady Gains in 2025

7 Large-Cap Stocks Headed for Strong, Steady Gains in 2025

While 2025 may not deliver massive returns, so MarketBeat analyst Chris Markoch shares his list of seven stocks primed for consistent performance.

Related Videos

3 Stocks Insiders Are Selling, But Analysts Still Love
NVIDIA Unveils Game-Changing Tech, But Stock Dips
The Future of Healthcare: 3 AI Stocks Leading the Way

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines